Valero Energy Corporation (NYSE:VLO) had its price target decreased by Oppenheimer from $65.00 to $60.00 in a research report sent to investors on Tuesday morning. The firm currently has an outperform rating on the stock.Valero Energy Corporation (NYSE:VLO) in last trading activity increased 2.00% to close at $47.03. Company weekly performance is -3.21% while its quarterly performance stands at -1.90%. Valero Energy Corporation (NYSE:VLO) is -19.99% away from its 52 week high.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a developer of oral drug delivery systems, on 3 December announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014, for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed’s common stock on Friday, October 31, 2014, in a private placement.On last trading day Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) decreased -7.99% to close at $5.41. Its volatility for the week is 7.37% while volatility for the month is 6.19%. ORMP’s EPS growth for past 5 years was -1.30%. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) monthly performance is -20.44%.
Amedisys, Inc. (NASDAQ:AMED), a leading home health and hospice company, announced that its Board of Directors has named Paul B. Kusserow as President and Chief Executive Officer and member of the Board of Directors. Kusserow will assume the role on December 16, 2014 from President and Interim CEO, Ronald LaBorde, who will remain a member of the senior management team in the role of Vice Chairman reporting directly to the CEO. LaBorde will also continue to serve as a member of the Board of Directors. On last trading day Amedisys Inc. (NASDAQ:AMED) increased 0.34% to close at $26.65. Its volatility for the week is 3.57% while volatility for the month is 3.31%. AMED’s sales growth for past 5 years was 1.00% and its EPS growth for past 5 years was -23.90%. Amedisys Inc. (NASDAQ:AMED) monthly performance is 5.54%.
HC Wainright began coverage on shares of eMagin Corp. (NYSEMKT:EMAN) in a research note issued on Tuesday. The firm set a “buy” rating and a $3.00 price target on the stock. HC Wainright’s price objective points to a potential upside of 32.66% from the stock’s previous close. eMagin Corp. (NYSEMKT:EMAN) has 5.70% insider ownership while its institutional ownership stands at 30.00%. In last trading activity company’s stock closed at $2.26.
Greif Bros. Corporation (NYSE:GEF) will begin trading ex-dividend on December 17, 2014. A cash dividend payment of $0.42 per share is scheduled to be paid on January 01, 2015. On Tuesday shares of Greif, Inc. (NYSE:GEF) closed at $45.37. Company’s sales growth for last 5 years was 2.80% and EPS growth for next 5 years is recorded as 8.67%.